Information & Referral

If you have come to our site seeking information, guidance, or referral services for yourself or another person, you have come to the right place. Wellspring is here to provide education and support to those who need assistance confronting the disease of alcoholism and drug dependence.

Information & Referral

Treatment Referrals
Suffering from an addiction problem? We can help you find a treatment facility. You can either browse through our local Treatment Directory, allow us to make suggested referrals by using our self-administered Screening Tool, or if you prefer speaking with one of our professionals, call our confidential Referral Helpline. We are available Monday through Friday from 8 a.m. to 9 p.m. You can also contact us via email at While not intended to diagnose a substance abuse problem, each of these options will help narrow your search for a program that best meets your needs. Note that the options provided do not represent an exhaustive list of all available programs or constitute an endorsement of particular programs. However, these are programs we have worked with and have consistently received positive feedback from those who have accessed their services. If you live outside of Middlesex County New Jersey, you can get help now by calling the New Jersey Addiction Services Hotline anytime at 844-276-2777. You can also access the New Jersey Mental Health Cares Information and Referral Helpline at 1-866-202-HELP (4357).
If you live outside of New Jersey, reach out to the National Council on Alcoholism and Drug Dependence at or 212-269-7797 to find your nearest local resources.
Jason Surks Memorial Resource Center
The Jason Surks Memorial Prevention Resource Center at Wellspring serves as a clearinghouse for free information about alcohol, tobacco and other drugs. Explore our vast collection of online information and helpful links, or visit us at our East Brunswick, NJ location to access free pamphlets, posters and DVD lending library.
More than just a physical and web-based library, our Resource Center is people. If you need assistance planning an educational program, need information for a health fair, or would like to contract with our staff to provide presentations in your community, please call us at 732-254-3344 or send us an email request at

Drug to Treat Alcohol Use Disorder Shows Promise among Drinkers with High Stress

Drug to Treat Alcohol Use Disorder Shows Promise among Drinkers with High Stress

NIH-funded multi-site clinical trial suggests that smokers may also benefit

A new medication that targets part of the brain's stress system may help reduce alcohol use in people with alcohol use disorder (AUD), according to a new study by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health.

"Medications have become an important tool for treating alcohol use disorders, but current medications are not effective for all people with AUDs," noted NIAAA Director George F. Koob, Ph.D. "We're committed to developing new medications to provide effective therapy to a broader spectrum of people with AUDs."

As reported online in the journal Neuropsychopharmacology, researchers led by Raye Litten, Ph.D., acting director of the NIAAA Division of Medications Development, conducted a randomized clinical trial of a new compound, called ABT-436, designed to block the effects of vasopressin, a neuropeptide produced in the hypothalamus of the brain.

"Vasopressin helps to regulate the pituitary adrenal axis and other brain circuits involved in emotion," explained Dr. Litten. "As such, it plays a role in regulating stress, anxiety, and their interaction with AUD."

Dr. Litten, first author Megan Ryan and their NIAAA colleagues worked with NIAAA's multi-center Clinical Investigations Group, to recruit 144 alcohol-dependent adult men and women for the 12-week study. During a 28-day baseline period, female participants consumed at least 28 drinks per week, while male participants consumed at least 35 drinks per week. Participants were then randomized to receive either placebo tablets or ones containing the ABT-436 compound. Researchers monitored participants' alcohol consumption, as well as their mood changes and smoking habits, as these are known to co-vary with alcohol consumption.

Researchers found that participants receiving ABT-436 experienced more days of alcohol abstinence than those receiving the placebo. In particular, participants who reported high levels of stress appeared to respond better to ABT-436, in that both the frequency of their drinking and the number of heavy drinking days they experienced decreased.

"Our findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress," said first author Ryan, a clinical project manager in the NIAAA Division of Medications Development.

Smokers may be another population that could benefit from ABT-436. In addition to its effects on alcohol consumption, study participants receiving the new compound experienced a reduction in smoking. The researchers suspect that ABT-436 might be targeting the same areas in the brain that relate to withdrawal and stress, and, in the process, influencing both tobacco and alcohol use disorders. Additional research is needed to determine if that is the case.